January 2022- Endo Pharmaceuticals Inc. declared the release of data from a population pharmacokinetic (PK) modeling and simulation study, assessing the potential dosing flexibility of AVEED, a testosterone undecanoate, in hypogonadal men.
June 2021- Novartis AG announced that 177Lu-PSMA-617 upgraded entire survival and radiographic progression-free survival for men suffering from metastatic castration-resistant prostate cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3973
Published Date: Aug 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving market growth owing to the rapidly growing geriatric population across the world, and the high prevalence of testosterone deficiency among people worldwide.
The market is anticipated to attain a CAGR of ~4% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Bayer AG, Endo Pharmaceuticals Inc., Eli Lilly & Company, Kyowa Kirin International plc, Mylan N.V., and others.
The hospital's segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.